Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NC410 in advanced solid tumors
NCT04408599Phase 2Terminated
- Sponsor
- NextCure, Inc.
- Start
- Jun 2020
- Primary completion
- Jul 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of NC410 in solid tumor, ovarian cancer, gastric cancer (GC) and 1 more (7 arms), sponsored by NextCure, Inc. Primary endpoint: Number of Participants With Treatment-emergent Adverse Events. Started Jun 2020; status: terminated.
02
Drugs
NC410
03
Conditions
solid tumorovarian cancergastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04408599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04408599.